AASLD The Liver Meeting 2023

TLM 2023: The simple noninvasive tool may be an alternative to FIB-4, researchers said, and the new data may have implications for NAFLD surveillance.

The predictive algorithm uses FibroScan-captured CAP and LSM data plus 5 clinical variables to identify advanced fibrosis in persons with MASLD.

TLM 2023: The burden of CAD is similar between persons with hepatic steatosis at low and high ASCVD risk, but rate of MACE is higher in the low-risk population.

TLM 2023: Use of rifaximin significantly reduced mean number of OHE episodes as well as hospital contacts, including ED visits and admissions.

TLM 2023: Investigators found that the protective effects of statin therapy against late stage liver disease increased with age older than 51 years.

TLM 2023: Relying solely on a primary diagnosis for overt hepatic encephalopathy underestimates the actual rate, length of stay, and costs of OHE hospitalizations.

TLM 2023: In participants with metabolic dysfunction-associated steatotic liver disease, retatrutide 8 mg and 12 mg resolved steatosis in >85% of subjects.

NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.

The shift in naming for diseases historically known as nonalcoholic fatty liver disease will be top of mind at The Liver Meeting 2023. Get a quick look at why.

We took The Liver Meeting's 11 journey maps to educational sessions and focused on 4 that will be of interest to primary care.